CPG
VTVT icon

Cornerstone Planning Group’s vTv Therapeutics VTVT Stock Holding History

Cornerstone Planning Group’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19
Closed -$268 – 1692
2024
Q4 		$268 Hold
19
– – ﹤0.01% 1303
2024
Q3 		$265 Hold
19
– – ﹤0.01% 1214
2024
Q2 		$277 Hold
19
– – ﹤0.01% 1157
2024
Q1 		$449 Hold
19
– – ﹤0.01% 960
2023
Q4 		$219 Hold
19
– – ﹤0.01% 858
2023
Q3 		$359 Hold
19
– – ﹤0.01% 948
2023
Q2 		$555 Buy
+19
New +$604 ﹤0.01% 1444
2022
Q4 		$740 Buy
+19
New +$628 ﹤0.01% 1411

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cornerstone Planning Group's VTVT Position: Q1 2025 in Review

Cornerstone Planning Group sold out of vTv Therapeutics (VTVT) in Q1 2025, closing a stake of 19 shares — an estimated $268 sold.

Cornerstone Planning Group first reported a position in VTVT in Q4 2022 and held it in 8 quarters. The position peaked at $740 in Q4 2022. 21 funds tracked by Wall St. Rank hold VTVT as of Q1 2025.

  • Cornerstone Planning Group reported no remaining vTv Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cornerstone Planning Group sold 19 vTv Therapeutics shares in Q1 2025, an estimated $268.
  • Cornerstone Planning Group first reported a position in vTv Therapeutics in Q4 2022 and held it in 8 quarters.
  • Cornerstone Planning Group's vTv Therapeutics position peaked at $740 in Q4 2022.
  • 21 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2025.

Based on Cornerstone Planning Group's 13F filing for Q1 2025, filed 30 Apr 2025.